Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Fragrance Creators Association (Fragrance Creators) issued the following statement from President & CEO Farah K. Ahmed acknowledging the Administration'sefforts to advance U.S. innovation:

"Fragrance Creators recognizes thenew Executive Order onAdvancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy, which aligns well with our industry's priorities related to biomanufacturing.The Associationhas met with the Administration, includingmeetings with theWhite HouseNational Economic Council, sharing solutions that empower the fragrance industry's ability to responsibly advance an adaptable and sustainable economywhile ensuring human, community, and environmental needs are prioritized and justly integrated, both here and around the world. Because the fragrance value chain's success is dependent on a healthy planet, we heavily invest and deeply understand the connection between nature and science.Supply chain resilienceparticularly in the space of biotechnology and biomanufacturingis of utmost importance, with biotechnology being a critical piece in protecting natural ingredient biodiversity. It is equally important to recognize there are many critical natural fragrance ingredients that must continue to be imported because they cannot be grown successfully in the U.S. Our members continually analyze supply chains to ensure natural materials are sourced responsibly so native ecosystems are preserved.

"As a multibillion-dollar industry and an integral part of the nation'scritical infrastructure, our members are proud of their current support and reliance on the skills and talents of our diverse American workforce.We commend the Administration for including a commitment to diversifying the biotechnology workforce further. Biotechnology is a rapidly evolving discipline, and we support streamlining regulations to ensure that products quickly and safely come to market.Fragrance Creators continues our active engagement with the Environmental Protection Agency and have advanced solutions to the backlog of approvals of newer, greener fragrance chemistries and we look forward to strengthening our partnership with the Administration to advance U.S. innovation in this area as well."

###

Fragrance Creators Association is the trade association representing the majority of fragrance manufacturing in North America. We also represent fragrance-related interests along the value chain. Fragrance Creators' 60+ member companies are diverse, including large-, medium-, and small-sized companies that create, manufacture, and use fragrances and scents for home care, personal care, home design, fine fragrance, and industrial and institutional products, as well as those that supply fragrance ingredients, including natural extracts and other raw materials that are used in perfumery and fragrance mixtures. Fragrance Creators established and administers the Congressional Fragrance Caucus, ensuring ongoing dialogue with members of Congress and staff. We are an active participant in IFRA and have a designated representative on the IFRA Board to help ensure the associations' membership is represented in global discussions and the North American perspective is considered in global fragrance positions and policies. Fragrance Creators also produces The Fragrance Conservatory, the comprehensive digital resource for high-quality information about fragrancewww.fragranceconservatory.com. Learn more about Fragrance Creators atfragrancecreators.orgfor people, perfume, and the planet.

Contact: Malory Todd

[emailprotected]

Related Images

Image 1

This content was issued through the press release distribution service at Newswire.com.

Featured Image for Fragrance Creators Association

Featured Image for Fragrance Creators Association

Link:
Fragrance Creators Statement in Support of Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and...

Sana Biotechnology Inc. (NASDAQ: SANA) stock fell -1.04% on Friday to $6.64 against a previous-day closing price of $6.71. With 1.49 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.45 million shares. The 52-week range on SANA shows that it touched its highest point at $26.60 and its lowest point at $3.92 during that stretch. It currently has a 1-year price target of $13.33.

Lithium Stocks In The Spotlight

Here's a company undiscovered by Wall Street and trading below $0.30 per share which just recently uncovered 8 high-quality targets on unexplored ground, and drills will be turning later this year. Very few investors know about it yet so the ground-floor opportunity below $0.30 won't be around much longer. It's a brand new breed of lithium explorer all you need to do is click and the name and trading symbol is yours.

It's all in the FREE report you can get here..

Sponsored

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was down-trending over the past week, with a drop of -3.21%, but this was down by -21.33% over a month. Three-month performance surged to 61.17% while six-month performance rose 15.68%. The stock lost -73.04% in the past year, while it has lost -57.11% so far this year. A look at the trailing 12-month EPS for SANA yields -1.61 with Next year EPS estimates of -2.37. For the next quarter, that number is -0.53. This implies an EPS growth rate of -37.80% for this year and -12.40% for next year.

At present, 187.63 million SANA shares are outstanding with a float of 168.88 million shares on hand for trading. On Jul 14, 2022, short shares totaled 22.35 million, which was 11.78% higher than short shares on Jun 14, 2022. In addition to Dr. Steven D. Harr M.D. as the firms Pres, CEO & Director, Dr. Richard C. Mulligan Ph.D. serves as its Exec. Vice Chairman & Head of SanaX.

Through their ownership of 85.43% of SANAs outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.91% of SANA, in contrast to 27.48% held by mutual funds. Shares owned by individuals account for 14.37%. As the largest shareholder in SANA with 5.79% of the stake, Baillie Gifford & Co. holds 11,011,462 shares worth 11,011,462. A second-largest stockholder of SANA, Canada Pension Plan Investment Bo, holds 10,175,000 shares, controlling over 5.35% of the firms shares. SSgA Funds Management, Inc. is the third largest shareholder in SANA, holding 8,594,413 shares or 4.52% stake. With a 5.35% stake in SANA, the Canada Pension Plan is the largest stakeholder. A total of 10,175,000 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.60% of SANA stock, is the second-largest Mutual Fund holder. It holds 6,854,877 shares valued at 46.68 million. Scottish Mortgage Investment Trus holds 2.94% of the stake in SANA, owning 5,586,264 shares worth 38.04 million.

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that its UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of $18.00 and a low target of $7.00, the average target price over the next 12 months is $12.75. Based on these targets, SANA could surge 171.08% to reach the target high and rise by 5.42% to reach the target low. Reaching the average price target will result in a growth of 92.02% from current levels.

It is also common to use earnings estimates to evaluate a firms growth potential and to determine trading strategy. SANA will report FY 2022 earnings on 03/22/2023. Analysts have provided yearly estimates in a range of -$1.64 being high and -$2.30 being low. For SANA, this leads to a yearly average estimate of -$1.94. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sana Biotechnology Inc. surprised analysts by $0.04 when it reported -$0.47 EPS against a consensus estimate of -$0.51. The surprise factor in the prior quarter was $0.30. Based on analyst estimates, the high estimate for the next quarter is -$0.39 and the low estimate is -$0.53. The average estimate for the next quarter is thus -$0.48.

Insiders traded SANA stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 3,594 shares were bought while 0 shares were sold. The number of buy transactions has increased to 8 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 103,683 while 60,333 shares were sold.

See the original post:
Get in on Sana Biotechnology Inc.'s (SANA) buy-in window today! - SETE News

HSINCHU, Sept. 11, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines.

NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes.

"We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," said Sherif Bayoumy, the General Manager of Medtreq Medical Equipment.

The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technology to make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level."

About Metreq Medical Equipment Bahrain

Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity.

About Brain Navi

Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/brain-navi-biotechnology-announced-partnership-with-distributor-medtreq-medical-equipment-to-enter-the-middle-east-and-egypt-with-naotrac-neurosurgical-robot-301621013.html

SOURCE Brain Navi Biotechnology Co., Ltd.

Original post:
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac...

The biotech sector is one of the most dynamic and unpredictable industries. While some companies struggle to stay afloat, others thrive with the help of intelligent management and timely product launches. Biotech stocks are volatile, but these companies offer lucrative investment opportunities if you know where to look. Keep reading to learn more about the biotech sector and our top picks for 2022. Our list will help you find the best stocks to invest in now and in the future, no matter how volatile this sector becomes. These markets have proven growth potential due to their current size or recent expansion efforts. Each company on this list offers value as a long-term holding regardless of market fluctuations.

Avidity Biosciences is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics. The companys lead candidate is CADATE-19, a potent antisense oligonucleotide, or ASO, designed to treat hypercholesterolemia. CADATE-19 has completed a Phase III clinical trial, and Avidity plans to submit a Neplannedg Application in 2021. If approved, CADATE-19 could capture a large share of the hypercholesterolemia treatment market, where the current market leader has an 80% share. The company also has a preclinical drug for Huntingtons disease. This rare genetic disorder causes nerve and muscle degeneration, leading to cognitive impairment, mood changes, and death. Overall, Avidity Biosciences has a strong product pipeline for treating several rare diseases, including hypercholesterolemia, hemophilia, and Huntingtons. In addition, the company has a good chance of success, given that its lead products have already completed Phase III clinical trials.

Syndax Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing drugs to treat rare diseases. The companys lead product is Texas, an intravenous treatment for patients with hereditary ATTR amyloidosis, an incurable, degenerative muscle disease that often leads to heart failure. Texas is currently in Phase III clinical trial. If approved, the drug will be reserved only for patients with ATTR amyloidosis who have already undergone a liver transplant. Syndax PharmaceuticalIn addition, s is also developing SD-101, a treatment intended to treat hereditary ATTR amyloidosis. If approved, SD-101 could capture a large share of the genetic ATTR amyloidosis treatment market, which is currently under $1 billion. Overall, Syndax Pharmaceuticals is a strong company with a good chance of success with its lead products. Although hereditary ATTR amyloidosis is a rare disease, the number of patients with this condition is expected to grow.

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering and developing drugs based on RNA interference, or RNAi. The companys lead product is S1AL19, a treatment for patients with familial amyloidosis, a rare genetic disorder that causes the buildup of a protein called amyloid in the organs and tissues. S1AL19 is currently in Phase III clinical trial. If approved, the drug could capture a large share of the familial amyloidosis treatment market, which is currently worth $1 billion annually. In addition, the company also has a preclinical cure for hereditary ATTR amyloidosis, a rare genetic disorder affecting the heart and kidneys. Overall, Alnylam Pharmaceuticals is a strong company with a good chance of success with its two lead products. Familial amyloidosis is a rare disease, but the number of patients with this condition is expected to grow.

Travel Therapeutics Holdings is a biopharmaceutical company focused on developing therapies for neurological diseases. The companys lead product candidate is CT1819, an intravenous treatment for patients with hereditary ATTR amyloidosis. Travel Therapeutics drug is currently in Phase II/III clinical trial. If approved, CT1819 could capture a large share of the genetic ATTR amyloidosis treatment market, which is currently worth $1 billion annually. The company also has, In addition, there clinical drug candidates for familial amyloidosis. Overall, Cerevel Therapeutics Holdings is a strong company with a good chance of success with its two lead products. Like hereditary ATTR amyloidosis, familial amyloidosis is a rare disease, but the number of patients with this condition is expected to grow.

Biotech stocks are notoriously volatile, and its important to remember that a single good or bad day can wipe out months of progress. That being said, the top biotech stocks for 2022 are poised for significant gains over the long term. These companies have various innovative products in their pipelines, from RNA-based therapeutics to RNAi-based drugs. With support from stakeholders and the market, these biotech stocks could dramatically outperform the broader market in 2022 and beyond.

Excerpt from:
Top Biotechnology Stocks To Buy In 2022 - Best Stocks

JCMRrecently broadcasted a new study in its database that highlights the in-depth market analysis with future prospects of Biotechnology Algae Cultivation (Micro Algae) market. The study covers significant data which makes the research document a handy resource for managers, industry executives and other key people get ready-to-access and self analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. Some of the key players mentioned in this research are Cellana, DENSO, Ecoduna, Solix Biofuels, Sapphire Energy, Algenol Biofuels, LGem, Solazyme, Cyanotech, Seambiotic, Mialgae, Neoalgae

Get Access to Free sample Report PDF @jcmarketresearch.com/report-details/1445407/sample

COVID-19 is an infectious disease caused by the most recently discovered novel corona virus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks.

In addition, production and supply chain delays were also witnessed during the second quarter which poised a challenge to the Biotechnology Algae Cultivation (Micro Algae) market, since end-user industries were still not operating at their full capacity.

Enquire for customization in Report @jcmarketresearch.com/report-details/1445407/Biotechnology-Algae-Cultivation-(Micro-Algae)

What are the markets problems in Biotechnology Algae Cultivation (Micro Algae)?

Changing regulatory landscapes, operational barriers, and the emergence of alternative technologies are all impacting the Biotechnology Algae Cultivation (Micro Algae) industry.

What are the various types of segments covered in the Biotechnology Algae Cultivation (Micro Algae) Market?

By Type Euglenophyta (Euglenoids) Chrysophyta (Golden-Brown Algae and Diatoms) Pyrrophyta (Fire Algae) Chlorophyta (Green Algae) Rhodophyta (Red Algae) Paeophyta (Brown Algae) Xanthophyta (Yellow-Green Algae) OthersBy Application Food Fertilizer and Agar Pollution Control Energy Production

Who are the top key players in the Biotechnology Algae Cultivation (Micro Algae) market?

Cellana, DENSO, Ecoduna, Solix Biofuels, Sapphire Energy, Algenol Biofuels, LGem, Solazyme, Cyanotech, Seambiotic, Mialgae, Neoalgae

Which region is the most profitable for the Biotechnology Algae Cultivation (Micro Algae) market?

The emerging economies in the Asia Pacific region will be the lucrative markets for Biotechnology Algae Cultivation (Micro Algae) products. .

What is the current size of the Biotechnology Algae Cultivation (Micro Algae) market?

The current market size of global Biotechnology Algae Cultivation (Micro Algae) market is estimated to be USD XX in 2021.

Get Discount instant FLAT40% Discount on full Biotechnology Algae Cultivation (Micro Algae) Report @ jcmarketresearch.com/report-details/1445407/discount

North America is the regions largest market for Biotechnology Algae Cultivation (Micro Algae).

North America includes countries such as the US, Canada, and Mexico. North America is the second-largest consumer and producer of electricity, after Asia Pacific. The US and Canada, which are among the largest consumers in this region as well as globally, constitute the largest share of the Biotechnology Algae Cultivation (Micro Algae) market.

Secondary Research:

This Biotechnology Algae Cultivation (Micro Algae) research study made extensive use of secondary sources, directories, and databases such as Hoovers, Bloomberg BusinessWeek, Factiva, and OneSource to identify and collect information useful for a technical, market-oriented, and commercial study of the global portable generator market. Other secondary sources included company annual reports, press releases, and investor presentations, white papers, certified publications, articles by recognized authors, manufacturer associations, trade directories, and databases.

Biotechnology Algae Cultivation (Micro Algae) Primary Research:

Various sources from both the supply and demand sides were interviewed during the Biotechnology Algae Cultivation (Micro Algae) primary research process to obtain qualitative and quantitative information for this report. Primary sources included industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations from all segments of the value chain of this industry. To obtain and verify critical qualitative and quantitative information, in-depth interviews were conducted with a variety of primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants.

Estimation of Biotechnology Algae Cultivation (Micro Algae) Market Size

The total size of the Biotechnology Algae Cultivation (Micro Algae) market was estimated and validated using both top-down and bottom-up approaches. These methods were also widely used to estimate the size of various market sub segments. The following research methodologies were used to estimate market size:

Extensive secondary research was used to identify the industrys key players.

The revenues generated by the markets leading players in molecular diagnostics have been determined through primary and secondary research.

All percentage shares, splits, and breakdowns were calculated using secondary sources and confirmed using primary sources.

TABLE OF CONTENTS OF Biotechnology Algae Cultivation (Micro Algae) Market Report

1 INTRODUCTION

1.1 Biotechnology Algae Cultivation (Micro Algae) study objectives1.2 Biotechnology Algae Cultivation (Micro Algae) definition1.3 Biotechnology Algae Cultivation (Micro Algae) inclusions & exclusions

1.4 Biotechnology Algae Cultivation (Micro Algae) market scope1.5 Biotechnology Algae Cultivation (Micro Algae) report years considered1.6 Biotechnology Algae Cultivation (Micro Algae) currency1.7 Biotechnology Algae Cultivation (Micro Algae) limitations1.8 Biotechnology Algae Cultivation (Micro Algae) industry stakeholders1.9 Biotechnology Algae Cultivation (Micro Algae) summary of changes

2 RESEARCH METHODOLOGY 2.1 Biotechnology Algae Cultivation (Micro Algae) research data

2.2 Biotechnology Algae Cultivation (Micro Algae) market breakdown and data triangulation2.3 Biotechnology Algae Cultivation (Micro Algae) scope2.4 impact of covid-19 on Biotechnology Algae Cultivation (Micro Algae) industry2.5 Biotechnology Algae Cultivation (Micro Algae) market size estimation

3 Biotechnology Algae Cultivation (Micro Algae) EXECUTIVE SUMMARY

4 Biotechnology Algae Cultivation (Micro Algae) PREMIUM INSIGHTS

4.1 attractive opportunities in Biotechnology Algae Cultivation (Micro Algae) market4.2 Biotechnology Algae Cultivation (Micro Algae) market, by region 4.3 Biotechnology Algae Cultivation (Micro Algae) market in North America, by end user & country 4.4 Biotechnology Algae Cultivation (Micro Algae) market, by application 4.5 Biotechnology Algae Cultivation (Micro Algae) market, by end user

5 Biotechnology Algae Cultivation (Micro Algae) MARKET OVERVIEW 5.1 Biotechnology Algae Cultivation (Micro Algae) introduction5.2 covid-19 Biotechnology Algae Cultivation (Micro Algae) health assessment5.3 Biotechnology Algae Cultivation (Micro Algae) road to recovery

5.4 covid-19 Biotechnology Algae Cultivation (Micro Algae) economic assessment5.5 Biotechnology Algae Cultivation (Micro Algae) market dynamics

5.6 Biotechnology Algae Cultivation (Micro Algae) trends5.7 Biotechnology Algae Cultivation (Micro Algae) market map5.8 average pricing of Biotechnology Algae Cultivation (Micro Algae) 5.9 Biotechnology Algae Cultivation (Micro Algae) trade statistics5.8 Biotechnology Algae Cultivation (Micro Algae) value chain analysis5.9 Biotechnology Algae Cultivation (Micro Algae) technology analysis5.10 Biotechnology Algae Cultivation (Micro Algae) tariff and regulatory landscape

5.11 Biotechnology Algae Cultivation (Micro Algae): patent analysis5.14 Biotechnology Algae Cultivation (Micro Algae) porters five forces analysis

6 Biotechnology Algae Cultivation (Micro Algae) MARKET, BY APPLICATION

6.1 Biotechnology Algae Cultivation (Micro Algae) Introduction6.2 Biotechnology Algae Cultivation (Micro Algae) Emergency6.3 Biotechnology Algae Cultivation (Micro Algae) Prime/Continuous

7 Biotechnology Algae Cultivation (Micro Algae) MARKET, BY END USER 7.1 Biotechnology Algae Cultivation (Micro Algae) Introduction7.2 Biotechnology Algae Cultivation (Micro Algae) Residential7.3 Biotechnology Algae Cultivation (Micro Algae) Commercial7.4 Biotechnology Algae Cultivation (Micro Algae) Industrial

8 GEOGRAPHIC ANALYSIS

8.1 Biotechnology Algae Cultivation (Micro Algae) Introduction8.2 Biotechnology Algae Cultivation (Micro Algae) industry by North America8.3 Biotechnology Algae Cultivation (Micro Algae) industry by Asia Pacific 8.4 Biotechnology Algae Cultivation (Micro Algae) industry by Europe8.5 Biotechnology Algae Cultivation (Micro Algae) industry by Middle East & Africa8.6 Biotechnology Algae Cultivation (Micro Algae) industry by South America

9 Biotechnology Algae Cultivation (Micro Algae) COMPETITIVE LANDSCAPE 9.1 Biotechnology Algae Cultivation (Micro Algae) Key Players Strategies9.2 Biotechnology Algae Cultivation (Micro Algae) Market Share Analysis Of Top Five Players9.3 Biotechnology Algae Cultivation (Micro Algae) Market Evaluation Framework9.4 Revenue Analysis Of Top Five Biotechnology Algae Cultivation (Micro Algae) Market Players9.5 Biotechnology Algae Cultivation (Micro Algae) Company Evaluation Quadrant9.6 Biotechnology Algae Cultivation (Micro Algae) Competitive Leadership Mapping Of Start-Ups9.7 Biotechnology Algae Cultivation (Micro Algae) Competitive Scenario

10 Biotechnology Algae Cultivation (Micro Algae) COMPANY PROFILES 10.1 Biotechnology Algae Cultivation (Micro Algae) Major Players10.2 Biotechnology Algae Cultivation (Micro Algae) Startup/Sme Players

11 APPENDIX 11.1 Insights Of Biotechnology Algae Cultivation (Micro Algae) Industry Experts11.2 Biotechnology Algae Cultivation (Micro Algae) Discussion Guide11.3 Biotechnology Algae Cultivation (Micro Algae) Knowledge Store11.4 Biotechnology Algae Cultivation (Micro Algae) Available Customizations11.5 Biotechnology Algae Cultivation (Micro Algae) Related Reports11.6 Biotechnology Algae Cultivation (Micro Algae) Author Details

Buy instant copy of Biotechnology Algae Cultivation (Micro Algae) research report @ jcmarketresearch.com/checkout/1445407

Find more research reports on Biotechnology Algae Cultivation (Micro Algae) Industry. By JC Market Research.

About Author:

JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:https://jcmarketresearch.com/Contact-Details

JC Market Research

Mark Baxter (Head of Business Development)

Phone: +1 (925) 478-7203

Email: sales@jcmarketresearch.com

Visit link:
Comprehensive Report on Biotechnology Algae Cultivation (Micro Algae) Market 2022 Trends, Growth Demand, Opportunities & Forecast To 2030 ...

Article content

BEIJING & GUANGZHOU, China Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co., LTD. (FineImmune) to co-develop cell-based therapeutic drugs targeting intracellular tumor-associated antigens. Biocytogen will use its proprietary TCR-mimic antibody platform to discover fully human antibody sequences that will be further developed using FineImmunes unique cell therapy platform.

Biocytogens TCR-mimic antibody development platform utilizes its proprietary fully human antibody RenMiceTM (RenMabTM and RenLite mice) that have been further engineered to express a human leukocyte antigen (HLA) gene. Antibodies against intracellular tumor-associated antigens are subjected to advanced high-throughput antibody screening technologies to discover antibodies with high specificity and affinity.

Most tumor antigens are intracellular, and our TCR-mimic platform provides a solution for developing antibodies against these valuable targets, said Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen. TCR-mimic antibodies generated by our TCR-mimic platform have potentials to be developed into multiple drug modalities such as T cell engagers, bispecific/multispecific antibodies and CAR-T therapies. We are pleased to collaborate with FineImmune to explore the application of our antibodies in the field of cell therapies.

FineImmune is a pioneering T cell therapy company, and has solved multiple critical barriers in the microenvironment of solid tumors by using multiple proprietary technology platforms, such as GSOP for T-cell engineering, HAP for TCR identification, CMP for personalized TCR-T cell production and in vivo T-cell delivery platform (TDP). FineImmunes product pipelines include TCR-T, CAR-T, TAL, TIL, etc. The company developed the first personalized neoantigen-specific TCR-T cell therapy, which is in phase I clinical trial now. In addition, FineImmune possesses technologies for the precision prediction of the efficacy and side effects of immunotherapy, enabling healthcare professionals to provide effective and safe immunotherapy to patients with common malignant tumors.

T cells play an important role in treating cancers. Biocytogens advanced TCR-mimic platform makes it possible for us to develop T cell therapies against crucial but low-expressed intracellular tumor antigens, said Dr. Penghui Zhou, Founder and Chief Technology Officer of FineImmune. We focus on providing efficient and safe immunotherapy using advanced technologies. This collaboration will promote the development of new cell therapeutic drugs and the expansion of the potential of immunotherapy to benefit patients.

About the TCR-Mimic Platform Biocytogens T Cell Receptor (TCR)-Mimic platform utilizes HLA-expressing fully human antibody mice (HLA/RenMice) to generate antibodies to intracellular tumor-associated antigens when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogens high-throughput antibody screening platform aims to swiftly identify TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody sequences against multiple intracellular targets have been obtained, and their efficacies have been verified in vitro and in vivo. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.

About Biocytogen Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The companys pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. On September 1, 2022, Biocytogen was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 02315.HK. For more information, please visit http://en.biocytogen.com.cn.

About FineImmune Guangzhou FineImmune Biotechnology Co., Ltd. is an innovation driven company based in China. The company is mainly engaged in the development of solid tumor immunotherapy drugs and related businesses. It has solved key technical bottlenecks in solid tumor immunotherapy and possesses core technologies. A number of T-cell therapy products for solid tumors are in clinical trials, as well as diagnostic reagents for accurate identification of effective populations. It has a 2000 square meter immunotherapy R&D laboratory and a GMP production workshop for cell therapy products in Guangzhou Science City. The companys individualized TCR-T cell therapy product (new drug) has been carried out clinical research in the Affiliated Tumor Hospital of Sun Yat sen University. At present, more than 20 immune cell therapy products and technologies are under research and development. For more information, please visit http://www.fineimmu.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005284/en/

Contacts

Biocytogen Platform and Assets: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn

#distro

More:
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-Based Cell Therapy - Financial Post